Bioventus vs Glaukos
BVS and GKOS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BVS and GKOS compare
Glaukos is the larger company, worth 13 times as much as Bioventus ($14.0B against $1.1B).
Glaukos grew revenue faster over the last twelve months (41.5% versus 3.1% for Bioventus).
Bioventus keeps more of each dollar of sales as profit, with a net margin of 9.4% compared with −30.7% at Glaukos.
Bioventus scores higher on the StockData Score (12 against 7 for Glaukos), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BVS | GKOS |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $14.0B |
| Share price | $13.32 | $237.60 |
| Change, 1 year | 96.8% | 208% |
| Change, 5 years | −18.8% | 317% |
| Beta (5Y) | 0.85 | 1.06 |
| Employees | 930 | 1,094 |
| StockData Score | ||
| Total score | 12 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 5 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.3× | – |
| P/S | 1.9× (better) | 22.9× |
| P/B | 4.9× (better) | 20.5× |
| EV/EBITDA | 16.6× | – |
| P/FCF | 11.9× | – |
| FCF yield | 8.4% (better) | −0.09% |
| Fair value | $15.80 | $70.14 |
| Margin of safety | 15.7% (better) | −239% |
| Growth | ||
| Revenue growth (TTM) | 3.1% | 41.5% (better) |
| Revenue growth, 5Y average | 12.1% | 17.7% (better) |
| Profitability | ||
| Gross margin | 68.7% (better) | 60.7% |
| Operating margin | 10.0% (better) | −31.6% |
| Net margin | 9.4% (better) | −30.7% |
| FCF margin | 16.2% (better) | −2.0% |
| Return on equity | 28.0% (better) | −26.0% |
| Return on invested capital | 12.7% (better) | −24.9% |
| Financial health | ||
| Debt / equity | 1.09 | – |
| Net debt / EBITDA | 2.62 | – |
| Interest coverage | – | −39.4× |
| Current ratio | 1.69 | 5.04 (better) |
| Altman Z-score | 2.41 | 34.36 (better) |
| Piotroski F-score | 8 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | −0.14% | – |
| Shareholder yield | −0.14% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 71.2% | 103% |
| Held by insiders | 29.0% | 5.3% |
| Insider net buying, 12 months | −$313K (better) | −$69.1M |
| Short interest, % of float | 5.3% | 6.9% |
Go deeper
- BVS stock overview
- BVS income statement
- BVS valuation and score
- GKOS stock overview
- GKOS income statement
- GKOS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.